Tri Locum Partners LP Buys Shares of 742,574 Evolus, Inc. (NASDAQ:EOLS)

Tri Locum Partners LP acquired a new position in Evolus, Inc. (NASDAQ:EOLS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 742,574 shares of the company's stock, valued at approximately $8,198,000. Evolus comprises 1.7% of Tri Locum Partners LP's portfolio, making the stock its 22nd biggest position. Tri Locum Partners LP owned 1.17% of Evolus at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in EOLS. KBC Group NV bought a new stake in Evolus in the fourth quarter worth $49,000. IFP Advisors Inc lifted its stake in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after acquiring an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Evolus during the 4th quarter valued at about $106,000. Quantbot Technologies LP purchased a new stake in Evolus during the 4th quarter valued at about $118,000. Finally, Tradition Wealth Management LLC grew its position in Evolus by 18.2% during the 4th quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock worth $144,000 after acquiring an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on EOLS. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday, April 9th. HC Wainwright restated a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. Barclays increased their price objective on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Finally, BTIG Research began coverage on Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Evolus has a consensus rating of "Buy" and a consensus target price of $23.75.

Insider Activity at Evolus

In related news, insider David Moatazedi sold 6,251 shares of the firm's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the transaction, the insider now owns 508,619 shares of the company's stock, valued at $6,306,875.60. This trade represents a 1.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $60,147.36. Following the completion of the sale, the chief marketing officer now directly owns 95,671 shares in the company, valued at approximately $1,268,597.46. This represents a 4.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 60,575 shares of company stock worth $794,369 over the last ninety days. 6.10% of the stock is owned by corporate insiders.

Evolus Stock Up 1.6 %

Evolus stock traded up $0.19 during trading hours on Friday, hitting $11.99. 511,725 shares of the stock traded hands, compared to its average volume of 666,765. Evolus, Inc. has a one year low of $8.67 and a one year high of $17.82. The company has a market cap of $762.28 million, a PE ratio of -13.19 and a beta of 0.97. The firm's 50-day moving average price is $12.02 and its two-hundred day moving average price is $12.80. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.